Browsing Tag
London Stock Exchange
330 posts
Avacta (AVCT) at AACR 2026: What the San Diego data presentations actually mean if you’re holding shares through the trial
Avacta Therapeutics (AIM: AVCT) is presenting two posters at AACR 2026 in San Diego. Here is what investors need to understand about conference data versus clinical trial readouts and which milestones actually move the stock.
Insig AI plc (AIM: INSG) wants a Nasdaq future, but is this a growth pivot or a riskier reinvention?
Insig AI plc says FY27 revenue could more than double as it explores Nasdaq and digital assets. Read what this means for INSG now.
Sorted Group Holdings plc just sold its core business for £1. What exactly is left now?
Sorted Group Holdings plc is selling its main subsidiary for £1 and becoming an AIM cash shell. Read what this means for shareholders and what comes next.
Cavendish plc (AIM: CAV) holds revenue steady, but the real story is strategic endurance
Cavendish plc held FY26 revenue near £56m and stayed profitable in both halves. Read what the update reveals about growth, cash, risk, and AIM markets.
Tracsis (LSE: TRCS) acquires Vesputi GmbH to plant its digital ticketing flag in Germany
Tracsis (TRCS) acquires German digital ticketing firm Vesputi for €5.8m, targeting Germany's Mobilitybox platform and public transport market. Read full analysis.
SSE plc lifts full-year EPS guidance as £33bn investment plan advances ahead of schedule
SSE plc raises EPS guidance to 147-152p, accelerates network investment 60%, and confirms 14.5 TWh renewables output. Read what it means for investors.
McBride (LSE: MCB) to acquire Eurotab Group to cement Unit Dosing leadership in Europe
McBride plc agrees to buy Eurotab Group for EUR 40m to strengthen Unit Dosing leadership in Europe. Read the full strategic analysis.
Defence Holdings (LSE: ALRT): Can Project Ixian deliver the UK’s first sovereign-AI defence contract?
Defence Holdings (LSE: ALRT) investor roadmap. Project Ixian contract progress, new CEO Andrew Roughan, UK defence spending tailwinds, and key risks explained.
How Fulcrum Metals (AIM: FMET) is turning 100-year-old mine waste into a multi-metal asset as gold trades near $4,700
Fulcrum Metals (AIM: FMET) advances towards maiden MRE with 70%+ cyanide-free gold recovery and critical minerals upside at Kirkland Lake. Read the full analysis.
Avacta (AIM: AVCT) investor roadmap: The milestones that matter between now and the AVA6103 data readout in late 2026
Avacta (AVCT) faces two clinical data readouts in 2026. This investor roadmap maps every milestone, risk, and signal to watch through the AVA6103 Phase 1 readout.